NDT Pharmaceuticals Inc (NDTP)

[Ecomike]

I think we are very close to seeing the SEC filing on $NDTP.

In the mean time, I am going to start going over the science and research paper history here of the NDTP Nano Delivery Technology Pharmaceutical birth history and science again and will be adding more research paper links and clues and details on the big words and science, and try to explain them in laymans terms as much possible.

Here is what I got a copy of today, that has some interesting info.

It was published in 2014, a year after CCA,LLC., now NDTP was formed.

https://cdn.discordapp.com/attachments/462311906129084418/752228555840290846/Oral_Delivery_of_Bioencapsulated_Protein.pdf

It should be an eye open for all of you. It is a pdf file.

The authors of that paper are from the Univ of So. Florida (Michael Fountain's play ground till he retired at the beginning of the summer this year) and Univ of Pennsylvania (Mathias/ Dr. Cohen/Larry Kubin....NDTP) and here is one I will be sharing on Ihub. The last author name listed is a UPennMed, guy, paper is dated 2014, a year after CCA, LLC, now know as NDTP, was first formed with Michael W Fountain as 10% founding shareholder.

It hit my radar on the key word searches (Paid access to research papers account I have).

"Oral Delivery of Bioencapsulated Proteins Across Blood–Brain and Blood–Retinal Barriers " is the Title

"Delivering neurotherapeutics to target brain-associated
diseases is a major challenge"

"Therefore, we investigated oral delivery of green fluorescence protein (GFP) or myelin basic protein (MBP) fused with the transmucosal carrier cholera toxin B subunit (CTB), expressed in chloroplasts (bioencapsulated within plant cells) to the brain and retinae of triple transgenic Alzheimer’s disease (3×TgAD) mice, across the blood–brain barriers (BBB)
and blood–retinal barriers (BRB)"

"However, no attention has been paid for developing oral drug
delivery systems to address neurological diseases." (dated 2014)

"Alzheimer’s disease (AD) is the most common neurodegenerative disease and the sixth leading cause of death in the United States, affecting an estimated 5.4 million Americans and 36 million people globally, with treatment cost exceeding US$600 billion, posing a major health-care challenge. (2014/2013 data)

By the year 2050, it is estimated that the incidence of AD will reach >100 million patients worldwide. One of the major pathological hallmarks of AD is the deposition of amyloid ß 42 ( Aß 42 ) as extracellular neuronal plaques."



The list of funding sources of the research grant is a who is who list.



There is lot more meat in the paper above for anyone that works in or has a heavy background in the Bio-chemical-medical and transport properties fields.

The 2016 SEC fillings, and the brand new $NDTP website(link below)

http://www.ndtpharma.com

confirm this is part of what the new $NDTP company and the original Private CCA, LLC business plan is all about.